La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Swedish Orphan Biovitrum a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Swedish Orphan Biovitrum..

Swedish Orphan Biovitrum (OTC:BIOVF) Azioni, Catena delle Opzioni

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SWEDISH ORPHAN BIOVITRUM ORD

Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.21, revenue of SEK6.84B

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) 2024 Q1 - Results - Earnings Call Presentation

Swedish Orphan Biovitrum AB reports Q1 results

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) 2024 Q2 - Results - Earnings Call Presentation

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript

Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB reports Q3 results

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript

BIOVF

MIRM

SWOBY

Press Releases

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

Earnings

Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio

Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A

Bulletin from Sobi's Annual General Meeting (AGM)

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Sobi has completed issues of class C shares

APLS

Swedish Orphan Biovitrum

Comments

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (BIOVF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO